XNCR (Xencor) Construction In Progress: $6.65 Mil (As of Mar. 2026)


XNCR Xencor Inc XNCR
52 GF Score
Price $15.60
GF Value $9.60
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Xencor Construction In Progress?

Xencor XNCR +3.38% 52 Construction In Progress is $6.65 Mil as of Mar. 2026. GuruFocus rates XNCR with a GF Score™ of 52/100 and a GF Value™ of $9.60 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Xencor's quarterly construction in progress declined from Sep. 2025 ($6.64 Mil) to Dec. 2025 ($6.63 Mil) but then increased from Dec. 2025 ($6.63 Mil) to Mar. 2026 ($6.65 Mil).

Xencor's annual construction in progress increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($7.22 Mil) but then declined from Dec. 2024 ($7.22 Mil) to Dec. 2025 ($6.63 Mil).

Xencor Construction In Progress Historical Data

* Premium members only.

The historical data trend for Xencor's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xencor Construction In Progress Chart

Xencor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 7.22 6.63

Xencor Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.92 6.81 6.64 6.63 6.65
XNCR
52GF Score
Xencor Inc XNCR
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xencor Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $6.65 Mil mean?
Xencor (XNCR) has a Construction In Progress of $6.65 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Xencor and its competitors.
Is Xencor's Construction In Progress too high?
Xencor's current Construction In Progress is $6.65 Mil. Overall, Xencor has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xencor's Construction In Progress compare to MGTX and WVE?
Xencor's Construction In Progress of $6.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Xencor and its competitors. Xencor's current Construction In Progress is $6.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xencor stock overvalued right now?
Based on GuruFocus' analysis, Xencor (XNCR) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.60, compared to a current price of $15.60 — trading 62.5% above its estimated fair value. The current Construction In Progress is $6.65 Mil. Xencor's overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Xencor (XNCR), the current Construction In Progress is $6.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xencor (XNCR) Overvalued in 2026?

Based on GuruFocus' analysis, Xencor stock appears to be overvalued. The current stock price of $15.60 is trading 62.5% above its estimated GF Value™ of $9.60. GuruFocus considers Xencor to be Significantly Overvalued.

Key valuation signals for XNCR:

  • Construction In Progress: $6.65 Mil
  • GF Value™: $9.60 vs. price of $15.60 (62.5% above fair value)
  • GF Score™: 52/100 with 7 warning signs

No single metric tells the full story. See the XNCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xencor Business Description

Other Exchanges XE9:Germany
Address 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
52GF Score

Get the complete analysis for XNCR

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.60
Price
$9.60
GF Value